Back to search results

ALN-4324 for Type 2 Diabetes Mellitus

This study is looking at how a single dose of ALN-4324 affects how your body uses insulin (insulin sensitivity) if you have type 2 diabetes. Researchers want to see if ALN-4324 can improve this. You might be able to join if you are an adult between 18 and 65 years old with type 2 diabetes, have a certain body mass index (BMI) and hemoglobin A1c (HbA1c) level, and are on stable doses of certain diabetes medications. The main goal is to measure changes in your insulin sensitivity over three months. This study is currently enrolling 24 participants.

Study design
This study is testing ALN-4324 against a placebo (an inactive substance) in 24 participants. Both ALN-4324 and the placebo are given as shots under the skin.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your insulin sensitivity will be measured from the beginning of the study up to three months later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07465224

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

Recruiting
PHASE2Ages 18–65InterventionalTreatment
Alnylam Pharmaceuticals
~24 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:ALN-4324Placebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in M-value
Measured over Baseline up to Month 3

Conditions

Type 2 Diabetes Mellitus (T2DM)

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Alnylam Pharmaceuticals

Who to contact

Alnylam Clinical Trial Information Line
[email protected]
1-877-ALNYLAM
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Is an adult patient with a confirmed diagnosis of T2DM
Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)

Exclusion

Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods

What this trial measures

  • Change from Baseline in M-valueBaseline up to Month 3

    M-value is measured as the glucose infusion rate at steady state